Vaxcyte (PCVX) to Post Quarterly Earnings on Wednesday

Vaxcyte (NASDAQ:PCVX) is projected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Vaxcyte to announce earnings of ($2.06) per share and revenue of $12.50 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the firm earned ($1.04) EPS. On average, analysts expect Vaxcyte to post $-8 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Vaxcyte Price Performance

NASDAQ PCVX opened at $53.53 on Tuesday. The company has a fifty day moving average price of $53.37 and a 200-day moving average price of $55.00. The firm has a market cap of $7.73 billion, a price-to-earnings ratio of -7.78 and a beta of 1.23. Vaxcyte has a 1 year low of $29.08 and a 1 year high of $65.00.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PCVX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, Zacks Research lowered Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $86.00.

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $57.28, for a total value of $572,800.00. Following the completion of the sale, the chief financial officer owned 104,395 shares of the company’s stock, valued at approximately $5,979,745.60. This trade represents a 8.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total value of $126,742.50. Following the completion of the sale, the chief operating officer directly owned 156,760 shares of the company’s stock, valued at approximately $8,830,290.80. This trade represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 91,396 shares of company stock worth $4,975,725 over the last ninety days. 3.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its position in shares of Vaxcyte by 115.2% in the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock valued at $1,113,000 after purchasing an additional 15,774 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Vaxcyte during the 1st quarter valued at $219,000. Caxton Associates LLP purchased a new stake in shares of Vaxcyte during the first quarter worth $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after acquiring an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers boosted its holdings in shares of Vaxcyte by 13.8% in the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after acquiring an additional 932 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.